Rare Disease Diagnosis Is Getting a New Standard of Care — and GeneDx Is Writing It

For the roughly 300 million people worldwide living with a rare disease, the path to diagnosis has historically looked less like medicine and more like endurance. The average patient visits multiple physicians over a span of four to seven years before a cause is identified — a timeline that, for infants in neonatal intensive care units, can mean the difference between early intervention and permanent disability. Genomic sequencing has long promised to shorten that window. The question, consistently, has been whether the scientific infrastructure existed to do it at clinical scale.

GeneDx has spent 25 years assembling an answer to that question. In 2025, the commercial and scientific evidence arrived simultaneously: exome and genome revenue reached $360 million, up 54 percent year-over-year; the FDA granted Breakthrough Device Designation for its flagship diagnostic tests; and a peer-reviewed research program earned recognition from JAMA among the most impactful of the year. Full-year revenues came in at $427.5 million, with 2026 guidance set at $540 to $555 million. These are not incremental milestones. They signal a company moving from diagnostic specialty to healthcare infrastructure.

But the financial trajectory only partially explains why GeneDx has become the company to watch in rare disease genomics. Beneath the revenue figures is a proprietary dataset, a regulatory designation, and a clinical evidence base that collectively position GeneDx not merely as a testing company, but as the interpretive layer through which genomic medicine will increasingly flow.

The Dataset That Changes What’s Possible in Rare Disease

At the core of GeneDx’s platform is GeneDx Infinity, the company’s proprietary rare disease genomic dataset now comprising more than one million sequenced exomes and genomes, over 2.5 million genetic tests, and more than 8 million phenotypic datapoints assembled over 25 years of clinical operation. The scale matters because rare disease diagnosis is fundamentally a pattern-recognition problem. The rarer the condition, the more comparator data is required to distinguish a pathogenic variant from background genomic noise. No other commercial entity has constructed a comparator library of this depth in rare disease specifically.

GeneDx’s two core clinical products, ExomeDx and GenomeDx, sit on top of this foundation. ExomeDx sequences the protein-coding regions of the genome, where the majority of disease-causing variants occur. GenomeDx sequences the entire genome, capturing structural and non-coding variants that targeted panels and chromosomal microarrays routinely miss. Both tests are powered by AI-driven variant interpretation, enabling clinicians to move from sequencing result to clinically actionable diagnosis faster than stepwise panel-based approaches allow.

The peer-reviewed research program built around GeneDx Infinity has become the company’s sharpest clinical argument. The Seqfirst-neo study, conducted in partnership with Seattle Children’s Hospital and the University of Washington and published in the American Journal of Human Genetics, found that at least 60 percent of Level IV NICU infants should be receiving rapid genome sequencing — a figure that reflects how dramatically current practice undershoots clinical need. The study was the first to apply exclusion rather than inclusion criteria for NICU genomic testing eligibility, a methodological shift that neonatologists and genetic counselors have begun adopting in clinical protocol revisions.

Alongside Seqfirst-neo, the GUARDIAN study — GeneDx’s genomic uniform newborn screening program spanning more than 17,000 participants — was recognized in JAMA’s 2025 Research of the Year Roundup, an honor reserved for the most impactful science published across all JAMA journals in a given year. In 2025 alone, GeneDx published 79 peer-reviewed studies, bringing its cumulative total to more than 1,100 publications, the largest clinical research portfolio in rare disease genomics by any commercial entity. The research output is not incidental to the business. It continuously revalidates the clinical utility of the GeneDx Infinity dataset and accelerates Medicaid and commercial payer coverage decisions in new markets.

From NICU Protocols to Prenatal Testing — A Pipeline Built on Evidence

In October 2025, FDA Breakthrough Device Designation was granted for both ExomeDx and GenomeDx, a designation reserved for diagnostics that demonstrate potential to provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. The designation provides GeneDx with an expedited FDA review pathway, including prioritized feedback and direct agency collaboration, accelerating the path toward formal agency clearance. For a company whose commercial model depends on expanding payer coverage and clinical adoption, this regulatory signal matters well beyond its symbolic weight. Medicaid coverage for GeneDx’s exome and genome tests now extends to 38 states in the pediatric outpatient setting, with rapid genome sequencing covered in 17 states for NICU applications.

The acquisition of Fabric Genomics, completed in May 2025 for up to $51 million, extends GeneDx’s reach beyond its own clinical laboratory. Fabric, now a wholly owned subsidiary, operates an AI-powered interpretation platform that health systems and global partners can deploy on-site, decoupling genomic interpretation from physical lab dependence. This architecture allows GeneDx to pursue markets in EMEA, APAC, and Latin America through flexible software-as-a-service and interpretation-as-a-service models rather than requiring laboratory buildout in each geography. The acquisition also unlocks a new recurring revenue dynamic that pure-play sequencing laboratory models cannot easily replicate.

Within its core testing portfolio, GeneDx launched ultraRapid genome sequencing, delivering results for critically ill NICU and PICU patients in as few as 48 hours — a turnaround that can materially alter clinical decision-making in time-sensitive neonatal cases. The company also introduced GenomeDx Prenatal, a phenotype-informed, trio-based whole genome sequencing test for pregnancies with fetal anomalies identified via ultrasound. The prenatal offering extends GeneDx’s addressable market earlier in the diagnostic lifecycle and positions the company in an adjacent clinical space where genomic testing penetration remains low.

The broadest clinical program GeneDx is supporting is the BEACONS initiative, the first multi-state genomic newborn screening program in the United States, launched with a $14.4 million NIH Common Fund award and led by Mass General Brigham and Ariadne Labs. GeneDx serves as the sequencing and interpretation laboratory for BEACONS, which aims to enroll up to 30,000 newborns across as many as 10 states over three years. The study is designed to generate the national evidence base that public health laboratories and state programs need before considering whole genome sequencing as a standard addition to existing newborn screening panels. GeneDx’s centrality to this program is both a scientific endorsement and a long-term commercial position: if BEACONS data supports national adoption of genomic newborn screening, GeneDx is the incumbent laboratory already operating at scale.

54 Percent Revenue Growth and a Regulatory Tailwind Heading Into 2026

GeneDx’s financial trajectory reflects the commercial consequences of 25 years of dataset accumulation reaching critical mass. Exome and genome test volume grew 30.5 percent year-over-year in 2025 to 97,271 results, with Q4 volume growth accelerating to 34.3 percent, suggesting momentum heading into 2026 rather than deceleration.

The strategic partnership with Komodo Health signals a new revenue vector: biopharma data services. By linking GeneDx Infinity’s rare disease genomic dataset with Komodo’s Healthcare Map, which covers more than 330 million de-identified patient journeys, GeneDx gains the ability to offer longitudinal rare disease intelligence that pharmaceutical companies need for health economics and outcomes research, clinical trial cohort identification, and AI model training. Rare disease drug development has historically been hampered by small, fragmented patient populations that are difficult to identify and recruit. GeneDx’s combined dataset addresses precisely that bottleneck.

GeneDx’s president and CEO Katherine Stueland was named to the TIME100 Health 2026 list, a recognition that landed during Rare Disease Month and underscored the broader cultural and institutional acknowledgment of rare disease diagnosis as a public health priority. Stueland’s tenure has been defined by the company’s shift from a specialty genetics laboratory operating within legacy panel testing markets to a platform company whose data asset is generating compounding diagnostic and commercial advantage. The leadership team she has assembled — including Dr. Mimi Lee as Chief Precision Medicine Officer and Dr. Linda Genen as Chief Medical Officer — reflects a deliberate build-out of clinical authority alongside commercial execution.

The risks are real. Policy headwinds surrounding Medicaid funding, the pace of FDA clearance for ExomeDx and GenomeDx following the Breakthrough Designation, and competitive pressure from laboratory consolidators all represent material uncertainties. Reimbursement remains inconsistent across state lines, and payer coverage decisions for newer testing modalities — including ultraRapid sequencing and GenomeDx Prenatal — are still evolving. The company’s 2026 guidance range implies continued investment in clinical programs and commercial infrastructure, with profitability expected to remain positive but constrained by scale-up costs in new market segments.

When the Infrastructure Becomes the Moat

Rare disease genomics is entering a phase where the central competitive variable is no longer sequencing technology — that has commoditized — but the depth of the clinical dataset used to interpret what the sequencing finds. The diagnostic value of any genomic test scales with how many patients’ genomic and phenotypic data the interpretive engine has seen. GeneDx’s 25-year head start in rare disease sequencing, now codified in GeneDx Infinity, creates a compounding advantage that newer entrants will struggle to replicate regardless of their sequencing hardware.

In 2025, that advantage converted — simultaneously — into durable commercial and regulatory recognition. An FDA Breakthrough Device Designation, a JAMA Research of the Year recognition, a $14.4 million NIH anchor program, and 54 percent revenue growth do not typically arrive in the same fiscal year. For healthcare systems, payers, and biopharma partners navigating the genomics landscape in 2026, the question is no longer whether GeneDx’s data asset matters. It is how deeply the infrastructure becomes embedded before anyone else closes the distance.